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Malaria and cryptosporidiosis, caused by apicomplexan parasites,
remain major drivers of global child mortality. New drugs for the
treatment of malaria and cryptosporidiosis, in particular, are of high
priority; however, there are few chemically validated targets. The
natural product cladosporin is active against blood- and liver-stage
Plasmodium falciparum and Cryptosporidium parvum in cell-culture
studies. Target deconvolution in P. falciparum has shown that clado-
sporin inhibits lysyl-tRNA synthetase (PfKRS1). Here, we report the
identification of a series of selective inhibitors of apicomplexan KRSs.
Following a biochemical screen, a small-molecule hit was identified
and then optimized by using a structure-based approach, supported
by structures of both PfKRS1 and C. parvum KRS (CpKRS). In vivo proof
of concept was established in an SCID mouse model of malaria, after
oral administration (ED90 = 1.5 mg/kg, once a day for 4 d). Further-
more, we successfully identified an opportunity for pathogen hopping
based on the structural homology between PfKRS1 and CpKRS. This
series of compounds inhibit CpKRS and C. parvum and Cryptosporid-
ium hominis in culture, and our lead compound shows oral efficacy in
two cryptosporidiosis mouse models. X-ray crystallography andmolec-
ular dynamics simulations have provided a model to rationalize the
selectivity of our compounds for PfKRS1 and CpKRS vs. (human)
HsKRS. Our work validates apicomplexan KRSs as promising targets
for the development of drugs for malaria and cryptosporidiosis.
malaria | cryptosporidiosis | tRNA synthetase
Malaria is caused by Plasmodium spp.; the most significantspecies from a disease perspective are Plasmodium falciparum
and Plasmodium vivax. In 2017, there were estimated to be 219
million clinical cases of malaria and 435,000 deaths from the
disease (1, 2). There is an urgent need for new drugs for
malaria to deal with the constant threat of drug resistance and
to provide new drugs for chemoprotection, prevention of
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transmission, and treatment of relapsing (vivax) malaria (2). In
humans, cryptosporidiosis is predominantly caused by Cryptospo-
ridium hominis and Cryptosporidium parvum. The recent Global
Enteric Multicenter Study has highlighted cryptosporidiosis as a
leading cause of moderate-to-severe diarrheal diseases in infants.
The association of cryptosporidiosis with death was the highest for
any pathogen in 6- to 18-mo-old children with moderate-to-severe
diarrhea (3–5). Cryptosporidiosis is estimated to lead to >200,000
deaths a year and is also associated with malnutrition, stunted
growth, and cognitive-development problems in children (6). The
currently approved drug nitazoxanide has poor efficacy, particularly
in the case of immune-compromised patients and malnourished
children, where there is no effective treatment (7, 8).
In the last decade, Plasmodium aminoacyl-tRNA synthetases have
received increased attention as new targets for antimalarial drug
discovery (9). Aminoacyl-tRNA synthetases catalyze aminoacylation of
tRNAs with their cognate amino acids in two stages (10). First, the amino
acid is activated by ATP to yield the AMP-activated amino acid, with
loss of pyrophosphate, followed by transfer of the amino acid onto
the tRNA. By way of example, a series of novel antimalarial bicyclic
azetidines, identified by phenotypic screening, were found to inhibit
cytosolic Plasmodium phenylalanyl-tRNA synthetase (11). These com-
pounds showed activity across multiple life stages of the parasite and
in vivo efficacy in a malaria mouse model. Malaria parasite genomes
encode two different lysyl-tRNA synthetases (KRSs) that play a role in
translation in either the cytoplasm (PfKRS1) or in the apicoplast (PfKRS2)
(9, 12, 13), while Cryptosporidium parasites and humans encode one
copy. Human KRS (HsKRS) is found in both the cytosol and mito-
chondrion and has additional roles within human cells (14).
Hoepfner et al. (15) discovered that the fungal secondary metabolite
cladosporin 1 (Fig. 1) was a nanomolar inhibitor of parasite growth in
both blood and liver stages of Plasmodium. They demonstrated that
cladosporin inhibited cytosolic PfKRS1 with >100-fold selectivity com-
pared with HsKRS. Unfortunately, cladosporin is not amenable to de-
velopment as a drug lead itself because of high metabolic instability (see
data we generated in Fig. 1), which would mean that it would not be
significantly orally bioavailable. In this work, we report the discovery and
optimization of drug-like inhibitors against PfKRS1 and CpKRS, which
showed oral activity in mouse models of malaria and cryptosporidiosis.
Results and Discussion
Characterization of KRS Enzymes. We produced recombinant PfKRS1
(77–583 and 80–583), CpKRS (46-end), and HsKRS (full-length)
proteins and developed biochemical assays based on the luciferase
ATP consumption assay (Kinase-Glo; Promega) (16), which was suitable
for the high-throughput screening, and the pyrophosphate generation
assay (EnzChek) (17) format for kinetic characterization of the enzymes.
The activities of recombinant enzymes were analyzed by monitoring
only the first stage of the aminoacylation reaction. This reaction is
suitable for high-throughput screening campaigns and makes the re-
action more amenable for steady-state kinetic studies. By using the
EnzChek assay, which monitors the production of pyrophosphate
(when coupled with pyrophosphatase), Km values were obtained for
PfKRS1, CpKRS, and HsKRS for ATP and L-lysine (Table 1 and SI
Appendix, Fig. S1 and Table S1). The Km values for the human enzyme
are significantly smaller than for the parasite enzymes. This may be due
to structural differences (see below) between the active sites of the
parasite and human enzymes. Even so, the Km values for ATP and L-lysine
obtained are comparable with KRSs from other species (https://www.
brenda-enzymes.org/) (18).
Hit and Lead Discovery. By using the luciferase ATP consumption
(Kinase-Glo) assay platform with sub-Km substrate concentrations (thus
biasing the assay toward identifying ATP-competitive inhibitors), the
GlaxoSmithKline malaria actives set of ∼13,000 compounds (the Tres
Cantos Antimalarial Set) (19) was screened against recombinant PfKRS1,
leading to the discovery of a PfKRS1 inhibitor, compound 2 (Fig. 1).
Compound 2 displayed similar levels of inhibition of PfKRS1 and growth
of P. falciparum to cladosporin 1. Compound 2 suffered from high met-
abolic instability (CLi > 50 mL·min
−1·g−1 in mouse liver microsomes);
however, in contrast to cladosporin 1, it was chemically tractable.
In the published structure of cladosporin bound to PfKRS1, clado-
sporin binds within the ATP binding pocket (20). The isocoumarin
moiety occupies the same space as the adenine ring of ATP, and the
pyran system occupies the same position as the ribose ring of ATP. The
two phenolic hydroxy groups of the isocoumarin ring form hydrogen
bonds with the side chain of E332 and the backbone NH of N339, while
the carbonyl interacts with a highly coordinated conserved water mol-
ecule (20). Screening hit 2 was cocrystallized with PfKRS1 and also
binds in the ATP binding pocket (Fig. 2A), in a similar fashion to cla-
dosporin, although the bicyclic core is rotated 30° with respect to cla-
dosporin. The chromone core stacks between the side chain of F342 on
one face and the side chains of H338 and R559 on the other. The ring
carbonyl forms an H-bond to the backbone NH of N339, mimicking the
N1 of adenine and the O1 OH of cladosporin. The amide carbonyl H-
bonds to a highly conserved water molecule coordinated by the side
chain of D558 and the backbone NHs of D558 and R559. The
cyclohexyl moiety projects into a pocket formed by the side chains
of R330, F342, and S344 and the backbone of L555 and G556. This
pocket is completed by the substrate lysine and is similar to that
occupied by the pyran ring of cladosporin, except that the cyclo-
hexyl ring probes deeper into the pocket (Fig. 2A).
Metabolite-identification studies suggested that hydroxylation
occurred in both the phenyl ring of the chromone and the cyclohexyl
Fig. 1. The structure of cladosporin 1, evolution of the lead 5 from the
screening hit 2. Enzyme data were obtained with the Kinase-Glo assay. MLM,
mouse liver microsomes.
Significance
Malaria and cryptosporidiosis are major burdens to both global
health and economic development in many countries. Malaria
caused >400,000 deaths in 2017, and cryptosporidiosis is esti-
mated to cause >200,000 deaths a year. The spread of drug re-
sistance is a growing concern for malaria treatment, and there is
no effective treatment for malnourished or immunocompromised
children infected with Cryptosporidium. New treatments with
novel mechanisms of action are needed for both diseases. We
present a selective inhibitor of both Plasmodium and Cryptospo-
ridium lysyl-tRNA synthetase capable of clearing parasites from
mouse models of malaria and cryptosporidiosis infection. This
provides very strong validation of lysyl-tRNA synthetase as a drug
target in these organisms and a lead for further drug discovery.
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ring. By preparing several potential metabolites, we identified the major
site of hydroxylation as carbon-6 at the phenyl ring. Addition of a
fluorine in the phenyl ring at C-6 blocked hydroxylation at the phenyl
ring of the chromone (compound 3; Fig. 1), and introduction of a
hydroxyl at the bridgehead of the cyclohexyl substituent was tolerated
without loss of potency, while reducing lipophilicity and intrinsic
clearance (compound 4). The cocomplex of 4 bound to PfKRS1 showed
that the ligand retained the binding mode of 2, conserving key H-bonds
from the core scaffold to the protein. The addition of the 6F atom did
not afford new interactions with the protein or ordered solvent. The
bridgehead hydroxyl was close to the side chain of E500, forming a weak
interaction (3.4 Å) and interacting with the ordered water network (SI
Appendix, Fig. S7). Addition of fluorines on the 4-position of the
cyclohexyl ring in 5 was tolerated and led to excellent metabolic stability,
both in mouse and human liver microsomes. (Fig. 1B and Table 2).
The complex of 5 bound to PfKRS1 showed that the addition of the
difluoro moiety on the cyclohexyl ring had minimal effect upon the
position of the ligand within the binding site with respect to 4, and there
was no evidence of protein rearrangement. In this complex, all polar in-
teractions were retained, although the H-bond between the bridge-head
OH and the side chain of Glu-500 had shortened to 3.0 Å (Fig. 2B).
Enzymatic studies of the inhibition of PfKRS1 by compound 5 were
performed by using the pyrophosphate generation (EnzChek) platform.
In the presence of saturating concentrations of both substrates, an IC50 of
210 nM was obtained (SI Appendix, Fig. S2A). To study the mechanism
of inhibition by compound 5, single-inhibition measurements were per-
formed at a fixed saturating concentration of one substrate and fixed
variable concentrations of the second substrate. Under our experimental
conditions, results showed a linear competitive inhibition vs. ATP with a
Ki of 32 nM and a linear uncompetitive inhibition vs. L-lysine with a Ki of
212 nM (SI Appendix, Fig. S2 B and C and Table S4). These results
indicate that compound 5 competes with ATP for the same binding site
and only binds in the presence of L-lysine, also suggesting a sequential
ordered kinetic mechanism where L-lysine is the first substrate to bind.
The results also show that, in the presence of high concentrations of
ATP, the binding affinity of compound 5 is reduced, whereas in the
presence of high concentrations of L-lysine, it is increased. Because the
mode of inhibition studies are performed at saturating concentration of
the cosubstrate, this leads to a lower, more potent Ki against ATP (L-
lysine is saturating) and a higher, less potent Ki against L-lysine (ATP is
saturating). It is noteworthy that the selectivity ratio for HsKRS/PfKRS1
(120-fold in Kinase-Glo) is similar to the 180-fold cellular selectivity
observed between P. falciparum parasites and human HepG2 cells.
It was reported that cladosporin binds to PfKRS1 in a cooperative
manner with L-lysine, leading to significant thermal stabilization
(increased melting temperature, Tm) (21). Notably, this stabilization
effect was not observed in the human counterpart. To determine
whether the chromone series retained a similar stabilization effect,
KRS enzymes were incubated with inhibitor and substrates (ATP
and L-lysine) in various combinations and gradually heated for ob-
servable shifts in Tm. For both PfKRS and CpKRS enzymes, a
marked shift (>2 °C) was observed when L-lysine was present, sug-
gesting an analogous codependent binding mode (Fig. 3). This
agrees with the results of the study of the mechanism of inhibition of
PfKRS1 by compound 5, in which there is a higher Ki determined for
this compound in the presence of L-lysine. In contrast, the HsKRS
exhibited a reduction in Tm in the presence of inhibitor and L-lysine.
Lead compound 5 showed good systemic exposure after oral
dosing with excellent oral bioavailability (F = 100%) and moderate
half-life (T1/2 = 2.5 h) (Table 2). A preliminary selectivity study in a 44
receptor/enzyme panel showed no activity at a concentration of
10 μM. The compound did not show inhibition of a range of cyto-
chrome P450 enzymes and did not inhibit hERG (EC50 > 100 μM).
While the compound has a good profile in in vitro assays, compound 5
showed toxicity in mice at higher doses (50 mg/kg orally) and was itself
not suitable for further progression. It is likely that the toxicity at
higher doses is due to inhibition of mammalian KRS. Indeed, at a
dose of 50 mg/kg, the blood concentration of compound 5 in mice
reached the EC50 for HepG2 cells. Nonetheless, this compound is a
drug-like tool compound to explore KRSs as drug targets.
Profile in Malaria. Compound 5 was active against both PfKRS1
(IC50 = 0.015 μM) and whole-cell bloodstream P. falciparum 3D7
(EC50 = 0.27 μM) and was selective compared with both the HsKRS
(IC50 = 1.8 μM) and HepG2 cells (EC50 = 49 μM). The drop-off from
enzyme to cell is probably due to multiple factors—but the two most
likely are that high levels of enzyme inhibition may be required for a
phenotypic response and the 1,000-fold increase in the concentration of
ATP between the enzyme assay and within the parasite cell (22), given
that ATP competes for binding with our inhibitors. The activity of 5
against parasites resistant to chloroquine Pf(K1) (EC50 = 0.51 μM) or
atovaquone Pf(TM90C2B) (EC50 = 0.52 μM) is similar to the drug-
sensitive strain Pf(NF54) (EC50 = 0.39 μM). We investigated the activity
against different life-cycle stages of malaria (Table 2). The lead com-
pound 5 showed comparable activity in liver schizonts (P. vivax liver
schizont EC50 = 0.95 μM) to asexual blood stages. The in vitro parasite
reduction ratio (PRR) assay (23) identified 5 as a compound with a slow
rate of killing, displaying an overall biological profile similar to other
Plasmodium protein-synthesis inhibitors acting on cytosolic targets and to
atovaquone (24) (SI Appendix, Fig. S3).
Fig. 2. Binding modes of ligands bound to PfKRS1 and CpKRS. (A) PfKRS1:
Lys:2 showing the binding mode of 2 (C atoms, gold) bound to the ATP site
of PfKRS1 (PDB ID code 6AGT) superimposed upon PfKRS1:Lys:cladosporin
(cladosporin C atoms, slate; PDB ID code 4PG3). (B) PfKRS1:5 showing binding
mode of 5 bound to PfKRS1 (PDB ID code 6HCU). (C) Overlay of CpKRS:Lys:
cladosporin (C atoms, gold; PDB ID code 5ELO) compared with PfKRS1:Lys:
cladosporin (C atoms, gray; PDB ID code 4PG3). Nonconserved residues within
the ligand binding site are labeled. (D) CpKRS:Lys:5 showing binding mode of 5
(C atoms, gold) in complex with CpKRS:Lys (C atoms, gray; PDB ID code 6HCW).
H-bonds are shown as dashed lines, and key residues are labeled for clarity.
Table 1. Kinetic parameters for KRS determined by using
EnzCheck
Enzyme Km ATP, μM* HillATP Km Lys, μM† HillL-Lys
PfKRS1 68 ± 3 — 413 ± 37 0.89 ± 0.04
CpKRS 346 ± 128 0.71 ± 0.09 1,045 ± 640 0.49 ± 0.06
HsKRS 2.22 ± 0.44 — 1.92 ± 0.37 —
*Determined in the presence of saturating concentration of the cosubstrate
L-lysine, 5 mM L-lysine for Pf and Cp and 0.075 mM for HsKRS.
†Determined in the presence of saturating concentration of the cosubstrate
ATP, 0.5 mM ATP for Pf, 2 mM for Cp, and 0.1 mM for HsKRS.
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The biological and pharmacokinetic profile was sufficient to
justify a rodent efficacy study. Compound 5 was evaluated in vivo
against P. falciparum parasites grown in the peripheral blood of
NODscidIL2Rγnull mice (SCID), engrafted with human erythrocytes
(25). Three days after infection, mice were dosed orally once a day for
4 d with 5, at concentrations up to 40 mg/kg (Fig. 4A). From dose–
response studies, a daily oral dose of ED90= 1.5 mg·kg
−1 (1.0–2.3 mg·kg−1)
(Fig. 4C), or its equivalent estimated daily exposure in blood
AUCED90 = 11,000 ng·h·ml
−1·d−1 (6,900–14,000 ng·h·ml−1·d−1)
(Fig. 4D), reduced parasitemia by 90% at day 5 of the study. The rate of
parasite clearance in vivo is consistent with the PRR data in vitro.
Pathogen Hopping: Cryptosporidiosis. There is a high level of sequence
identity within the active-site region of PfKRS1 and CpKRS (96%
identity) and an overall sequence identity of 47.7% and similarity of
64.6% across the entire protein. Furthermore, structurally, the active
sites are very similar. Therefore, we tested cladosporin, the screening
hit 2, and the lead compound 5 in a cellular assay against C. parvum.
The three compounds showed inhibition of parasite growth with EC50
of 0.7, 1.2, and 2.5 μM, respectively. Our lead 5 is similarly active
against a small panel of isolates: C. hominis (TU502) (EC50 = 6.0 μM)
and the C. parvum Iowa strain (EC50 = 1.3 μM). In time-kill curve
studies conducted by using C. parvum in the HCT-8 cell-culture system
(26), both cladosporin and compound 5 eliminated parasites at an ex-
ponential rate, consistent with other protein synthesis inhibitors studied
to date (SI Appendix, Fig. S4). Subsequently, a crystal structure was
determined of CpKRS in complex with cladosporin and L-lysine [Protein
Data Bank (PDB) ID code 5ELO] (Fig. 2C), showing retention of the
ligand binding mode compared with the PfKRS1 structure and the high
level of sequence conservation within the active site, with only two se-
quence differences at the base of the ligand binding site (PfKRS1 V328
S344 and CpKRS N293 A309). Further CpKRS:ligand structures were
obtained for several compounds within the chromone series, including
CpKRS:5 (Fig. 2D), showing 5 to bind in an identical manner to
CpKRS as to PfKRS1. In cryptosporidiosis, the parasite is found pre-
dominantly in the epithelial cells (enterocytes) in the gastrointestinal
tract (8), although it is thought that there may also be some parasites
present in the biliary tract. Therefore, it is likely that a compound used
for treating cryptosporidiosis would need to have a good exposure in the
gastrointestinal tract and possibly also some systemic exposure (27).
After oral dosing, compound 5 was completely bioavailable. However,
some compound was present in mouse stools (17% of oral dose), sug-
gesting that some biliary excretion had occurred. This raises the possi-
bility of deliberately utilizing enterohepatic recirculation to maintain
both gastrointestinal and systemic exposure. Compound 5 showed
in vivo efficacy in two different Cryptosporidium mouse models, the
NOD SCID gamma and INF-γ–knockout mouse models.
INF-γ–knockout mice (28, 29) were infected orally with Nluc-
expressing transgenic C. parvum oocysts. Treatment started upon pa-
tency 4 d postinfection (p.i.), and mice were treated orally once a day
for 7 d. Infection was monitored daily by luciferase measurements in
pooled feces of the entire cage. Mice were followed for 3 wk after
completion of drug treatment. Compound 5, when dosed orally at
20 mg/kg once a day for 7 d, reduced parasite shedding below detection
level, and this reduction was sustained for 3 wk after treatment had
stopped (Fig. 4E). NOD SCID gamma mice were infected with
C. parvum oocysts (26). Treatment started 7 d p.i., and mice were treated
orally once a day for 7 d. The study was run with four mice per cage;
infection was monitored by quantitative PCR on day eight for individual
mice, and data are shown as oocysts per milligram of feces. Compound 5
dosed orally at a concentration of 20 mg/kg once a day for 7 d showed 96%
reduction of parasite shedding comparable to paromomycin (Fig. 4F).
Molecular Basis of PfKRS1 Inhibitor Selectivity. Molecular dynamics
(MD) simulations were successful in reproducing the binding pose and
interactions of compound 5 observed in the co-crystal structure of PfKRS1
(SI Appendix, Fig. S5A). In addition to those interactions, the inhibitor was
found to be stabilized by hydrophobic contacts established between the
cyclohexyl moiety and the bound substrate L-lysine. Simulations performed
in the absence of L-lysine showed a notable destabilization of compound
5, suggesting a key role of L-lysine in the binding of PfKRS1 inhibitors
(SI Appendix, Fig. S5B). This was confirmed by both the structural
information and the thermal shift assays (Figs. 2 and 3).
MD simulations of HsKRS predicted a similar binding mode of
compound 5 to that in PfKRS1, and the per-residue contributions to
the ligand binding energy also showed very similar results (SI Ap-
pendix, Fig. S5 C and E). However, despite the overall high sequence
and structural similarity between PfKRS1 and HsKRS, two non-
conserved residues were present within the active site: V328 and
S344 in PfKRS1 correspond to bulkier residues Q321 and T337 in
HsKRS (Fig. 5 A–C). To investigate whether this subtle difference
might have an impact on the binding process of compound 5, both
enzymes were also simulated in the absence of inhibitor (apo systems),
with the main focus placed on the conformational features of the
binding pocket. In apo-PfKRS1, due to the smaller size of V328 and
S344 side chains, the ligand binding pocket remained accessible to
compound 5 (Fig. 5B). Conversely, in apo-HsKRS, the binding site
remained partially inaccessible due the extended side chain of Q321,
which formed a hydrogen-bond network with R323, T337, and E339
(Fig. 5C and SI Appendix, Fig. S6A). Hence, a disruption of the
hydrogen-bond interactions within the active site of HsKRS is required
to enable the binding of the inhibitor.
The comparison of apo and holo PfKRS1 and HsKRS systems also
showed significant differences in the dynamics of residues neigh-
boring the active site. In apo-PfKRS1, R330 was highly flexible and
Table 2. In vitro activity and DMPK profile of lead compound 5
Assay Data
P. falciparum 3D7 EC50 0.27 μM
P. vivax liver schizonts/hypnozoites EC50 (prophylactic mode) 0.95 μM/>10 μM
P. berghei liver schizonts EC50 0.9 μM
P. falciparum stage V gametocytes EC50 9.9 μM
P. falciparum male/female gamete formation EC50 >1 μM
FaSSIF solubility 255 μM
Microsomal stability CLint 1 (mouse), <0.5 (human) mL·min
−1·g−1
Hepatocyte stability CLint 0.5 (mouse), <0.5 (human) mL·min
−1·g−1
CYP inhibition (CYP1A2, 2D6, 2C9, 2C19, 3A4) IC50 >10 μM
Mouse PK intravenously (dose, Clb, AUC, T1/2, Vdss) 3 mg/kg, 3.4 mL·min
−1·kg−1, 890 μg·min/mL, 2.5 h, 1 L/kg
Mouse PK orally (dose, Tmax, Cmax, AUC0–1440, F%) 10 mg/kg, 2 h, 5.4 μg/mL, 1,300–3,000 μg·min/mL, 100%
Fig. 3. Heatmap showing effects of compounds 1 and 5 on the melting
temperature (ΔTm) of KRS enzymes.
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was stabilized only after binding of the inhibitor. Similar behavior
was observed for the loop 282–291, which was highly disordered in
the absence of the ligand, but became ordered upon ligand binding
(Fig. 5B and SI Appendix, Fig. S6C). This was corroborated by the
marked positive shift in PfKRS1’s Tm in the presence of inhibitor
and L-lysine compared with the apo state (Fig. 3). On the other hand,
in HsKRS, the equivalent R323 and loop 274–282 remained highly
stable, regardless of the presence of the ligand (Fig. 5C and SI Ap-
pendix, Fig. S6 B and C). Such ligand-induced stabilization observed
for the mobile loop and residues near the PfKRS1 active site could
potentially account for a more favorable binding of compound 5 to
PfKRS1 with respect to HsKRS. The CpKRS system exhibited be-
havior similar to PfKRS1: an accessible binding site and a high degree
of flexibility of the loop and R295 in the apo-state and dramatic
stabilization upon ligand binding, which, again, was supported by the
large observed shift in Tm from the apo state to the L-lysine plus in-
hibitor state (Figs. 3 and 5D and SI Appendix, Fig. S6 B and C). This
provided a rationale for the compound 5 affinity toward CpKRS.
The results of MD simulations suggested that the parasite KRS
selectivity vs. HsKRS observed for compound 5 was due to a com-
bination of two factors: (i) a more favorable (i.e., more accessible)
configuration of the binding site in the parasite enzyme, and (ii) a
higher degree of stabilization for the PfKRS1 and CpKRS residues
upon ligand binding. Our findings are in good agreement with pre-
vious experimental and structural studies that reported an increased
flexibility of PfKRS1 over HsKRS and suggested that the active-site
loops in aminoacyl-RNA transferases are likely to have a critical role
in specific ligand recognition (21, 30, 31). It is likely that full un-
derstanding of the observed selectivity can only be obtained by
reproducing the entire process of ligand binding to KRS.
In conclusion, identification of the molecular targets of pheno-
typic hits and subsequent target-based approaches to these targets is
a promising way to develop new antiinfective agents. PfKRS1 was
shown to be the target of the natural product cladosporin, which was
found to be active against P. falciparum in cell culture. Cladosporin
itself is not suitable for progression to animal studies, as it is not
metabolically stable or orally bioavailable. Given that cladosporin
has a complex synthesis with low overall yield (eight steps with an
overall yield of 8%) (32), chemical modification to improve the
metabolic stability looked challenging, and a long synthesis means
that the cost of goods would likely fall outside the Target Product
Profiles for malaria and cryptosporidiosis. Therefore, we carried out
a small-molecule screen against PfKRS1 to find an alternate che-
motype for optimization. Following optimization of a hit molecule (2),
we identified a metabolically stable and orally bioavailable compound
(5) which inhibited PfKRS1 selectively. A low oral dose (1.5 mg/kg
once a day for 4 d) of our KRS inhibitor, compound 5, reduced
parasitemia by 90% in the malaria SCID mouse model. These results
represent an in vivo validation of PfKRS1 as a promising antimalarial
target for drug development. We have also successfully undertaken
pathogen-hopping (33), demonstrating that this compound series in-
hibits CpKRS and the growth of C. parvum in vitro. Moreover, com-
pound 5 showed a reduction of parasite burden by two orders of
magnitude when dosed orally for 7 d in two different mouse models of
cryptosporidiosis. There are very few validated targets for cryptosporidi-
osis, and here we chemically validated in vitro and in vivo CpKRS as a
target for drug development.
We have carried out MD simulations to understand the observed
selectivity of compound 5 and other analogs for PfKRS1 and CpKRS
vs. HsKRS. MD simulations suggest that the selectivity observed for
compound 5 is due to a combination of a more favorable config-
uration of the binding site and a higher degree of stabilization upon
ligand binding in the parasite enzymes. This work represents a
strong validation of lysyl tRNA synthetase as a drug target in both
Fig. 4. In vivo efficacy of compound 5 in mouse models of malaria and cryptosporidiosis infections. (A) The in vivo efficacy data for compound 5 in P. falciparum-
infected SCID mice. (B) The levels of compound 5 in blood of the mice during the malaria efficacy experiment, 24 h after the first oral dose and 24 h after the
administration of the last dose on day 4. The symbols represent the same individuals depicted in plot A. (C) Determination of daily dose to reduce P. falciparum
parasitemia by 90% at day 5 of the experiment. (D) Determination of daily exposure in blood to reduce P. falciparum parasitemia by 90% at day 5 of the experiment.
(E) Efficacy of compound 5 in the Nluc-cryptosporidiosis INF-γ–knockout mouse model when dosed orally at a concentration of 20 mg/kg once a day for 7 d. Orange
bars show fecal parasite levels for mice treated with compound 5 and blue bars for the vehicle-treated control mice. At day 8, there is a 10,000-fold reduction in
parasite levels compared with control. n = 4 mice per group. (F) Efficacy of compound 5 in the cryptosporidiosis NOD SCID gamma mouse model when dosed orally
at a concentration of 20 mg/kg once a day for 7 d. Orange bars represent fecal parasite levels for mice treated with compound 5, green bars mice treated with
paromomycin (2,000 mg/kg), and blue bars for vehicle-treated control mice. At day 8, there is a 100-fold reduction in parasite levels compared with control.
Baragaña et al. PNAS | April 2, 2019 | vol. 116 | no. 14 | 7019
M
IC
RO
BI
O
LO
G
Y
CH
EM
IS
TR
Y
malaria and cryptosporidiosis in animal models. We have identified
a valuable tool compound, although further optimization is re-
quired in terms of both potency and selectivity to obtain a preclinical
candidate.
Materials and Methods
Full details are in SI Appendix. This includes the following information: (i) the
chemical synthesis of compounds described in the paper; (ii) the methods for
protein expression and purification, kinetic characterization of enzymes, screening
of library, and mode of inhibition studies; (iii) the methods for parasite assays
using the different life-cycle stages of P. falciparum and different species of
Cryptosporidium; (iv) methods for in vitro drug metabolism and pharmacokinetic
assay; (v) methods for in vivo pharmacokinetics and efficacy studies; (vi) details for
molecular modeling and dynamics simulations; (vii) details of X-ray crystallogra-
phy; (viii) ethical use of animals; and (ix) detailed author contributions. Ethical
approval for rodent experiments was given by the University of Vermont
Institutional Animal Care and Use Committee, The Art of Discovery Institutional
Animal Care and Use Committee (TAD-IACUC), Veterinäramt Basel Stadt, the
University of Dundee “Welfare and Ethical Use of Animals Committee,” and
the University of Georgia Animal Care and Use Committee. Human biological
samples were sourced ethically and used under informed consent.
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Fig. 5. Differential bindingmode of compound 5 to PfKRS1,HsKRS, and CpKRS.
(A) Sequence alignment of the active sites of PfKRS1, HsKRS, and CpKRS. Two
nonconserved residues suggested to be responsible for the selectivity of com-
pound 5 are highlighted in red boxes. (B–D) Multiframe representations of the
active site from the MD simulations of the active sites of PfKRS1 (B) (cyan),
HsKRS (C) (green), and CpKRS (D) (orange) in the absence (Upper) and pres-
ence (Lower) of compound 5. Lysine is shown in magenta, compound 5 is
shown in purple, and nonconserved residue labels are highlighted in boxes.
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